Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies Meeting Abstract
| Authors: | Hamilton, E. P.; Patel, M. R.; Rodon, J.; Hong, D. S.; Schram, A. M.; Janne, P. A.; LoRusso, P.; Sachdev, J. C.; Ou, S. H.; Buck, E. A.; O'Conner, M.; Waters, N.; Witt, K.; Cook, C. |
| Abstract Title: | Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368309106 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.TPS3665 |
| Notes: | Meeting Abstract: TPS3665 -- Source: Wos |
